AIP
MTCR

Ameritas Investment Partners’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Ameritas Investment Partners’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-555
Closed -$3K – 3300
2021
Q1 		$3K Hold
555
– – ﹤0.01% 3068
2020
Q4 		$4K Buy
+555
New +$5.09K ﹤0.01% 3014

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Investment Partners's MTCR Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2021, closing a stake of 555 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in MTCR in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q4 2020. 42 funds tracked by Wall St. Rank hold MTCR as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Metacrine, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 555 Metacrine, Inc. Common Stock shares in Q2 2021, an estimated $3K.
  • Ameritas Investment Partners first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Ameritas Investment Partners's Metacrine, Inc. Common Stock position peaked at $4K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.